cervical cancer | MediPaper Medical Communications Ltd.

Posts

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

24th April 2019/0 Comments/in Chemotherapy, Gynaecological Cancer, Haematology, ImmunoOncology, Immunotherapy, Oncology /by Stijn van den Borne, MSc

Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1

13th June 2018/0 Comments/in Gynaecological Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research, US FDA Onc\Haem Approvals /by News Feed

On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.